5301992025-07-012025-09-305301992025-09-305301992025-03-315301992025-04-012025-09-305301992025-07-012025-09-30in-capmkt:OtherExpenses1Member5301992025-04-012025-09-30in-capmkt:OtherExpenses1Member5301992025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15301992025-07-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25301992025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15301992025-04-012025-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss25301992025-07-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15301992025-04-012025-09-30ItemsThatWillBeReclassifiedToProfitAndLoss15301992025-07-012025-09-30AuditorDomain1iso4217:INRiso4217:INRxbrli:shares530199THEMISMEDNAINE083B01024THEMIS MEDICARE LIMITEDMain BoardEquity2025-04-012026-03-312025-11-132025-11-04INRLakhsQuarterlySecond quarterSingle segmentPharmaceutical2025-11-1312:00:002025-11-1313:00:00trueCash Flow IndirectDeclaration of unmodified opinion2025-07-012025-09-30UnauditedConsolidated77994100032364000812305000161083000182281000-1019090002493100002764900025745000320052000864211000-519060000-519060000164900016490000-5355500000017399000-36156000-741000-36897000-361564000-3689750009204000010-0.39-0.3900-0.39-0.391) The above Unaudited Financial Results were reviewed by the Audit Committee and have been considered and approved by the Board of Directors at its respective meeting held on November 13, 2025. <BR> 2) The above financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) as prescribed under section 133 of the Companies Act , 2013 read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and the Companies (Indian Accounting Standards) Rules, 2016. <BR> 3) The Company operates in a single Business segment i.e Pharmaceuticals and hence does not have any reportable segments as per Indian Accounting Standard (Ind AS) 108 - "Operating Segments". <BR> 4)The Board of Directors of the Company, at its meeting held on November 18, 2024, had approved the Scheme of Amalgamation ("Scheme") between Gujarat Themis Biosyn Limited ("GTBL") and the Company and their respective shareholders under sections 230 to 232 and other applicable provisions of the Companies Act, 2013, subject to receipt of necessary regulatory and other approvals. <BR> However, the Board of Directors of GTBL, at its meeting held on June 13, 2025 after evaluating new developments in the market decided to focus on its core business of fermentation-based pharmaceutical intermediates and active pharmaceutical ingredients and decided to revisit all its strategic options. Consequently, the GTBL Board reconsidered its earlier decision of merger and resolved not to proceed with the proposed merger. Accordingly, the GTBL Board has approved the withdrawal of the Scheme as permitted under clause 21 of the Scheme. <BR> In alignment with this decision, the Board of Directors of the Company in their meeting held on June 13, 2025 has resolved to withdraw the said Scheme of Amalgamation. Pursuant to this, the Company shall continue to focus on its core domestic formulations business with the objective of achieving long-term sustainable growth. <BR> 5) The company has received an approval for struck off M/s. Carpo Medicals Limited (UK), a wholly owned subsidiary company by issue of a gazette notification on 01st April 2025 for dissolution w.e.f 14th April 2025 by the Company House, UK. Accordingly, the company has provided for Investment Rs. 0.76 lacs and Receivable and advances amounting to Rs. 128.63 Lacs in the Financial Statement as the Company is in the process of obtaining approval from the Reserve Bank of India (RBI) under the Foreign Exchange Management Act (FEMA), 1999, for writing off the said investments. <BR> The company has disclosed the Investments, receivables and advances provided for, as an exceptional item in the Statement of Profit and Loss in accordance with Ind AS 1 and applicable accounting principles. Subject to approvals from RBI for striking off the said foreign subsidiary, as per the provisions of the FEMA and applicable ODI regulations, the amounts will be written-off. <BR> 6) Figures for the corresponding previous year/period have been regrouped/rearranged, wherever necessary, to make them comparable. <BR> 2025-04-012025-09-30UnauditedConsolidated17557180004412300017998410002853820003990390008101800049780100052351000512730006241710001991035000-1911940000-1911940000320100032010000-19439500000016042000-178353000-1021000-179374000-178351600-1000-179372600-10009204000010-1.94-1.9300-1.94-1.93Other Expenses320052000Other Expenses624171000168688400033852000002244000009605890003460000001225400015714000013562100028349040007644690000173427800081335000461180000621350001923866000030171400029900490000058249530009204000037080430003800083000-150003800068000176060000000176060000186500009098800000285698000779576000221120004453970004675090003329460001580031000713140002934200058500000017391870000020248850005824953000078676000367460000-6770700000-43900016656000-468660000600180000512730000924100001767300000000-278000000-710000154922000-36272000-18721000-42326000021730000-14840000000000000255450000000000000000000016933000178800000-68240000000000013580900010058000046020000423260000037405000157410000157410006559400081335000Items that will not be reclassified to profit and loss-1032000Share of Other Comprehensive Income of Associates and Joint Ventures accounted using equity method30000-1002000Items that will not be reclassified to profit and loss-2065000Share of Other Comprehensive Income of Associates and Joint Ventures accounted using equity method59000-2006000-260000-520000Items that will be reclassified to profit & loss10001000Items that will be reclassified to profit & loss46500046500000-741000-1021000UnauditedtrueKRISHAAN AND COtrue2027-07-31